Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:DBVOTCMKTS:HIPHNASDAQ:IMNNOTCMKTS:OTLC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AHIPHAmerican Premium Mining$0.00$0.00▼$0.00$6.44M2.071.92 million shs20,000 shsIMNNImunon$1.43-11.7%$1.07$0.37▼$3.65$25.09M2.133.60 million shs1.50 million shsOTLCOncotelic Therapeutics$0.06+11.7%$0.06$0.02▼$0.07$23.03M-0.67111,758 shs95,692 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%HIPHAmerican Premium Mining0.00%0.00%0.00%0.00%-50.00%IMNNImunon-2.41%+15.71%+102.50%+87.26%+32.79%OTLCOncotelic Therapeutics0.00%-4.89%-3.92%+21.03%+42.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AN/AN/AN/AIMNNImunon2.2569 of 5 stars3.42.00.00.03.00.01.3OTLCOncotelic Therapeutics1.2215 of 5 stars0.05.00.00.02.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AHIPHAmerican Premium Mining 0.00N/AN/AN/AIMNNImunon 2.75Moderate Buy$15.50983.92% UpsideOTLCOncotelic Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HIPH, IMNN, OTLC, and DBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025IMNNImunonD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/13/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$29.00 ➝ $17.005/7/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.003/26/2025IMNNImunonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/24/2025IMNNImunonD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AHIPHAmerican Premium Mining$70K0.00N/AN/AN/ANaNIMNNImunon$500K50.17N/AN/A$1.42 per share1.01OTLCOncotelic Therapeutics$70K328.97$0.02 per share3.12$0.03 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/A0.00N/AN/AN/AN/AN/AN/AIMNNImunon-$19.51M-$1.36N/AN/AN/AN/A-230.05%-128.98%8/13/2025 (Estimated)OTLCOncotelic Therapeutics-$7.90M-$0.01N/A∞N/AN/A-8.48%-3.09%N/ALatest HIPH, IMNN, OTLC, and DBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025IMNNImunon-$0.35-$0.28+$0.07-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/AOTLCOncotelic TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVInvesco DB G10 Currency Harvest FundN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AIMNNImunonN/A2.302.30OTLCOncotelic Therapeutics0.280.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVInvesco DB G10 Currency Harvest Fund85.24%HIPHAmerican Premium MiningN/AIMNNImunon4.47%OTLCOncotelic TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipDBVInvesco DB G10 Currency Harvest FundN/AHIPHAmerican Premium MiningN/AIMNNImunon5.00%OTLCOncotelic Therapeutics39.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableHIPHAmerican Premium Mining164.40 billionN/ANot OptionableIMNNImunon3017.54 million13.78 millionNot OptionableOTLCOncotelic Therapeutics20408.29 million246.93 millionNot OptionableHIPH, IMNN, OTLC, and DBV HeadlinesRecent News About These CompaniesOncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in StockholmApril 22, 2025 | globenewswire.comOncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023April 16, 2025 | globenewswire.comOncotelic Therapeutics Inc (OTLC)April 10, 2025 | nasdaq.comOncotelic Therapeutics Delays Yearly Report FilingMarch 31, 2025 | tipranks.comOncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAIMarch 31, 2025 | globenewswire.comOncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 ConferenceMarch 25, 2025 | globenewswire.comOncotelic Accesses Rapid IND Development Platform through Partnership with MedicilonFebruary 25, 2025 | globenewswire.comOncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 ConferenceFebruary 13, 2025 | globenewswire.comOncotelic Therapeutics Implements PDAOAI PlatformDecember 31, 2024 | globenewswire.comONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024November 6, 2024 | globenewswire.comONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICSOctober 28, 2024 | finance.yahoo.comONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024October 24, 2024 | finance.yahoo.comRussia faces new wave of drop in clinical trials for new drugsSeptember 30, 2024 | thepharmaletter.comAlibaba rises on report it will charge software service feeJuly 29, 2024 | uk.finance.yahoo.comProduct Manager Scott Myers to Present at 2nd Global Summit on Artificial IntelligenceJuly 29, 2024 | globenewswire.comONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGYJune 11, 2024 | globenewswire.comONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETINGMay 30, 2024 | globenewswire.comONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETINGMay 20, 2024 | globenewswire.comOncotelic Therapeutics Inc OTLCMay 19, 2024 | morningstar.comONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024May 16, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHIPH, IMNN, OTLC, and DBV Company DescriptionsInvesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.American Premium Mining OTCMKTS:HIPHAmerican Premium Mining Corporation focuses on supporting the blockchain ecosystem through proof-of-work and proof-of-stake mining of cryptocurrencies. The company was formerly known as American Premium Water Corporation and changed its name to American Premium Mining Corporation in May 2022. American Premium Mining Corporation is based in Playa Vista, California.Imunon NASDAQ:IMNN$1.43 -0.19 (-11.73%) Closing price 04:00 PM EasternExtended Trading$1.43 0.00 (0.00%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Oncotelic Therapeutics OTCMKTS:OTLC$0.06 +0.01 (+11.68%) As of 06/12/2025 03:51 PM EasternOncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
